DEVELOPMENT AND EVALUATION OF TITANIUM DIOXIDE-FREE FILM-COATED TABLETS CONTAINING DROTAVERINE HYDROCHLORIDE
DOI:
https://doi.org/10.22159/ijap.2026v18i1.56749Keywords:
Drotaverine, Drotaveraldine, Perparaldine, Titanium dioxide, Impurity profilingAbstract
Objective: Drotaverine is a spasmolytic drug commonly used for the symptomatic relief of smooth muscle contractions associated with gastrointestinal disorders, biliary dyskinesia and renal colic. In light of the anticipated prohibition of titanium dioxide (TiO2) in pharmaceutical coatings within the European Union, this study aimed to develop 80 mg drotaverine hydrochloride tablets employing an alternative titanium-free coating and to establish a validated analytical method for the determination and characterization of impurities in accordance with regulatory guidelines.
Methods: Two tablet prototypes containing drotaverine hydrochloride were manufactured in laboratory scale. A new high-performance liquid chromatography (HPLC) method for impurity determination in titanium-free coated drotaverine hydrochloride tablets was developed and validated according to ICH Q2(R2) guidelines. Stability studies were conducted, and emerging unknown impurity was analyzed using ultra-performance liquid chromatography coupled with mass spectrometry (UPLC–MS) and nuclear magnetic resonance (¹H and ¹³C NMR).
Results: During stability testing, an impurity with a relative retention time (RRT) of 2.05 was detected, exceeding the 0.2% threshold set by ICH Q3B(R2) for unidentified impurities. This impurity was identified as 6,7-diethoxy-1-(3,4-diethoxybenzoyl)isoquinoline (perparaldine). Based on its structural characterization, the reporting and qualification threshold for this impurity was proposed to be extended to 0.5%, ensuring acceptable product quality over at least two years of storage.
Conclusion: This work demonstrates an innovative approach by combining titanium-free formulation development with advanced analytical elucidation of novel impurities. Moreover, the validated HPLC method ensures regulatory compliance, reliable routine analysis, and robust quality control and stability assessment of this novel dosage form.
References
1. Shabbir S, Kulyar MF, Bhutta ZA, Boruah P, Asif M. Toxicological consequences of titanium dioxide nanoparticles (TiO2NPs) and their jeopardy to human population. BioNano Science. 2021;11(2):621-32. doi: 10.1007/s12668-021-00836-3, PMID 33520589.
2. Shi J, Han S, Zhang J, Liu Y, Chen Z, Jia G. Advances in genotoxicity of titanium dioxide nanoparticles in vivo and in vitro. Nano Impact. 2022;25:100377. doi: 10.1016/j.impact.2021.100377, PMID 35559883.
3. Chen Z, Wang Y, Ba T, Li Y, Pu J, Chen T. Genotoxic evaluation of titanium dioxide nanoparticles in vivo and in vitro. Toxicol Lett. 2014;226(3):314-9. doi: 10.1016/j.toxlet.2014.02.020, PMID 24594277.
4. European Food Safety Authority. Safety assessment of titanium dioxide (E171) as a food additive. EFSA J. 2021;19(5):e06301. doi: 10.2903/j.efsa.2021.06301.
5. European Union. Commission Regulation (EU) 2022/63 of 14 January 2022 amending Annexes II and III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council as regards the food additive titanium dioxide (E171). Official Journal of the European Union. 2022 Jan 14;L13:1 3.
6. Schoneker DR. Why would the EU want to ban titanium dioxide in pharmaceutical products? What would be the potential impact on patients? J Excipients Food Chem. 2022;13:94-8.
7. Blundell R, Butterworth P, Charlier A, Daurio D, Degenhardt M, Harris D. The role of titanium dioxide (E171) and the requirements for replacement materials in oral solid dosage forms: an IQ consortium working group review. J Pharm Sci. 2022;111(11):2943-54. doi: 10.1016/j.xphs.2022.08.011, PMID 35973604.
8. Thummala VR, Tharlapu SS, Rekulapalli VK, Ivaturi MR, Nittala SR. Development and validation of a stability-indicating RP-HPLC method for the estimation of drotaverine impurities in API and pharmaceutical formulation. Sci Pharm. 2013;82(1):99-115. doi: 10.3797/scipharm.1309-06, PMID 24634845.
9. Vitanyine Morvai M, Kovacs P, Kalmanne Mathe I, Jakab B, Vegeli. Paracetamol and drotaverine-containing composition. E. WO2001007024A2-1; 2001.
10. Pavel IZ, Heller L, Sommerwerk S, Loesche A, Al Harrasi A, Csuk R. Drotaverine a concealed cytostatic! Arch Pharm (Weinheim). 2017;350(1):e1700053. doi: 10.1002/ardp.201600289, PMID 27879007.
11. Ziyatdinova GK, Samigullin AI, Abdullina SG, Budnikov GK. Quantitative estimation of benzylisoquinoline derivatives by coulometric titration. Pharm Chem J. 2008;42(2):98-101. doi: 10.1007/s11094-008-0068-z.
12. Rele RV, Pratamesh P, Tiwatane P. A Non-aqueous potentiometric titration method for validation of imatinib mesylate from pharmaceutical dosages. Asia Jour Rese Chem. 2019;12(6):307-10. doi: 10.5958/0974-4150.2019.00056.7.
13. Rele RV. UV spectrophotometric estimation of drotaverine hydrochloride by zero order and area under curve methods in bulk and pharmaceutical dosage form. Res J Pharm Technol. 2018;11(12):5576-80. doi: 10.5958/0974-360X.2018.01014.4.
14. Abdallah O, Rashed N, El Olemy A, Hosam Eldin A. UV spectrophotometric determination of paracetamol in presence of drotaverine hydrochloride. J Adv Pharm Res. 2017;1(2):89-95. doi: 10.21608/aprh.2017.1977.
15. Padmavathi P, Das P, Krunal P, Subrahmanyam EV. Analytical method devlopment and validation for estimation of drotaverin Hcl in bulk and tablet formulation. Asian Journal of Biomedical and Pharmaceutical Sciences. 2013;3(22):75-8.
16. Mehmood Y, Mahmood RK, Akram W. Development and validation of UV-spectrophotometric meth-ods for quantitative estimation of drotaverine HCl injection. Pharm Methods. 2017;8(1):31-5.
17. Balan P, Carolin Nimila I, Chundi S, Movva VR, Rajasekar S. A validated RP-HPLC method for estimation of drotaverine HCL in pharmaceutical tablet dosage form. Int J Pharm Pharm Sci. 2011;3(4):77-80.
18. Azhlwar S, Ravi TK. Stability-indicating HPLC method for simultaneous determination of drotaverine and aceclofenac. Int J Pharm Pharm Sci. 2011;3(1):245-50.
19. Sahani S, Jain V. A novel reversed-phase high-performance liquid chromatography method for simultaneous estimation of drotaverine hydrochloride ethamsylate and tranexamic acid in tablet dosage form. Asian J Pharm Clin Res. 2018;11(6):121-5. doi: 10.22159/ajpcr.2018.v11i6.24777.
20. Vijay Kumar R, Rao VU, Anil Kumar N, Venkata Subbaiah B. A novel rapid and validated stability-indicating UPLC method for the estimation of drotaverine hydrochloride and ibuprofen impurities in oral solid dosage form. Sci Pharm. 2015;83(4):567-81. doi: 10.3797/scipharm.1503-02, PMID 26839839.
21. Tawfik SA, El Ragehy NA, Hegazy MA, Sedik GA. A reversed-phase-high performance liquid chromatography method for simultaneous determination of paracetamol caffeine drotaverine HCl and their related impurities with dissolution profiling of their tablets and greenness profile assessment. Biomed Chromatogr. 2023;37(2):e5539. doi: 10.1002/bmc.5539, PMID 36287616.
22. Koo OM. Pharmaceutical excipients: properties functionality and applications in research and industry. Hoboken, NJ: John Wiley & Sons; 2016.
23. Pawelczyk E, Opielewicz M. Kinetyka rozkladu lekow. XLIX. Kinetyka samoutlenienia chlorowodorku drotaweryny w fazie stalej. Acta Pol Pharm. 1978;35(3):311-9. PMID 696363.
24. European Medicines Agency. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. London: European Medicines Agency; 2003. Available from: https://www.ema.europa.eu/en/ich-q1a-r2-stability-testing-new-drug-substances-drug-products-scientific-guideline. [Last accessed on 22 Dec 2025].
25. European Medicines Agency. ICH Q2(R2) Validation of Analytical Procedures Scientific guideline. Amsterdam: European Medicines Agency; 2023. Available from: https://www.ema.europa.eu/en/ich-q2r2-validation-analytical-procedures-scientific-guideline. [Last accessed on 22 Dec 2025].
26. Li J, Wu Y. Lubricants in pharmaceutical solid dosage forms. Lubricants. 2014;2(1):21-43. doi: 10.3390/lubricants2010021.
27. Kawakita R, Sperger D, Chal B, Fogarty J, Mc Cormick M, To D. Using response surface methodology to quantify iron oxide levels needed to protect photolabile active pharmaceutical ingredients in oral solid dosage forms. J Pharm Sci. 2025;114(6):103778. doi: 10.1016/j.xphs.2025.103778, PMID 40164306.
28. Niemczyk K, Cieplucha A. A pharmaceutical composition comprising metamizole, drotaverine and caffeine. EP003749286B1; 2006.
29. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q3B(R2) Impurities in New Drug Products. Step 4 version; 2006 June 2. Geneva: ICH; 2006. Available from: https://database.ich.org/sites/default/files/Q3B%28R2%29%20Guideline.pdf. [Last accessed on 22 Dec 2025].
Published
Versions
- 07-01-2026 (2)
- 08-12-2025 (1)
How to Cite
Issue
Section
Copyright (c) 2026 MIROSLAW STROZIK, MAGDALENA STRZEBONSKA, KATARZYNA GRYCHOWSKA, KATARZYNA SKIBA, PAWEL ZAJDEL, WIKTOR TATARA
This work is licensed under a Creative Commons Attribution 4.0 International License.